Why Most CBD Products Don't Work: The Bioavailability Problem
The pharmacokinetics of CBD and why dose, formulation, and route of administration matter enormously
Oral CBD has only 6% bioavailability — meaning 94% of a typical dose is lost before reaching the bloodstream. Yet most commercial CBD products are dosed at 10–50mg, far below the 300–600mg used in clinical trials. Understanding CBD pharmacokinetics is essential for anyone trying to evaluate whether a product is likely to work.
The First-Pass Metabolism Problem
When you swallow a CBD capsule or gummy, the CBD is absorbed through the gut wall and travels directly to the liver via the portal circulation — before it ever reaches the rest of the body. In the liver, CBD is extensively metabolized by CYP3A4 and CYP2C19 enzymes, converting it primarily to 7-hydroxy-CBD and 7-carboxy-CBD. Most of this metabolized CBD is then excreted rather than entering systemic circulation. This process — called first-pass hepatic metabolism — is why oral CBD has only 6–19% bioavailability in most studies.
For comparison, intravenous CBD has 100% bioavailability (it bypasses the liver entirely). Inhaled CBD achieves 10–35% bioavailability. Sublingual CBD (held under the tongue for 60–90 seconds) achieves partial bypass of first-pass metabolism through absorption into the sublingual vasculature, achieving 12–35% bioavailability with faster onset than oral administration.
The Fat Meal Effect
One of the most clinically significant — and underappreciated — findings from CBD pharmacokinetics research is the dramatic effect of food on oral CBD absorption. The FDA's pharmacokinetic data from Epidiolex trials found that a high-fat meal increased CBD maximum plasma concentration (Cmax) by approximately 5-fold and total exposure (AUC) by approximately 4-fold compared to fasting conditions.
This means that the same 100mg oral CBD dose produces roughly 5x higher blood levels when taken with a high-fat meal (e.g., avocado toast, full-fat yogurt, nuts) compared to an empty stomach. The mechanism is straightforward: CBD is highly lipophilic (fat-soluble), and dietary fat in the gut increases its solubilization and absorption. This finding has major practical implications: patients who take CBD on an empty stomach may be receiving a pharmacologically sub-therapeutic dose, while the same dose with food might be effective.
The Dose Gap Between Research and Products
The most important number in CBD pharmacology is the dose used in clinical trials vs. the dose in commercial products. For anxiety: RCTs showing efficacy have used single doses of 300–600mg. For epilepsy: Epidiolex is dosed at 5–20mg/kg/day — 350–1,400mg/day for a 70kg adult. For sleep: studies have used 25–175mg. For psychosis: a 2020 RCT used 150–600mg/day.
Most commercial CBD products contain 10–50mg per serving. Even accounting for the fat-meal effect (which might 4–5x effective exposure), a 25mg CBD gummy taken with food delivers perhaps the equivalent of 100–125mg under fasting conditions — still well below the 300mg minimum used in anxiety RCTs. This dose gap is not a minor discrepancy; it is a fundamental challenge to the clinical relevance of most commercial CBD products. It does not mean these products have no effect — but it does mean that the evidence from clinical trials cannot be straightforwardly extrapolated to commercial products.
Improving Bioavailability: What Actually Works
Several strategies can meaningfully improve CBD bioavailability. The most practical: always take oral CBD with a high-fat meal. This alone can increase exposure 4–5x at no additional cost. Sublingual administration (tinctures held under the tongue for 60–90 seconds before swallowing) improves onset speed and modestly improves bioavailability by bypassing some first-pass metabolism.
More advanced formulations show promise in early research. Self-emulsifying drug delivery systems (SEDDS) — which pre-solubilize CBD in a lipid-surfactant mixture — improve absorption by 2–4x in animal studies. Nanoemulsions (CBD dispersed in water-soluble nano-droplets) show similar improvements. Liposomal CBD encapsulates CBD in phospholipid vesicles that may improve cellular uptake. However, most of these advanced formulations lack rigorous human pharmacokinetic data, and marketing claims often outpace the evidence.
Inhalation: High Bioavailability, Real Risks
Inhaled CBD (vaporized or smoked) achieves 10–35% bioavailability with rapid onset (2–10 minutes) and peak effects within 30 minutes — making it the most pharmacokinetically efficient oral-alternative route. For patients who need rapid symptom relief (acute anxiety, breakthrough pain), inhalation offers a pharmacokinetic profile that oral routes cannot match.
However, inhalation carries respiratory risks that must be weighed against the bioavailability benefit. Combustion produces carbon monoxide and carcinogens; vaporization reduces but does not eliminate respiratory toxicants. The 2019 EVALI outbreak (linked primarily to vitamin E acetate in illicit THC cartridges) highlighted the risks of unregulated vape products. For patients who choose inhalation, vaporization of flower at 170–185°C appears to be the lowest-risk option. The bioavailability advantage of inhalation is real, but so are the risks.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.